Ocuphire Pharma Schedules 2024 Annual Meeting of Stockholders for June 11
Ticker: IRD · Form: DEF 14A · Filed: Apr 29, 2024 · CIK: 1228627
Sentiment: neutral
Topics: proxy statement, annual meeting, Ocuphire Pharma, director election, auditor ratification
TL;DR
<b>Ocuphire Pharma will hold its virtual 2024 Annual Meeting of Stockholders on June 11, 2024, to elect directors and ratify auditors.</b>
AI Summary
Ocuphire Pharma, Inc. (IRD) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Ocuphire Pharma, Inc. will hold its 2024 Annual Meeting of Stockholders on June 11, 2024, at 4:00 p.m. ET. The meeting will be conducted virtually via live webcast, accessible at https://viewproxy.com/ocuphire/2024/htype.asp. Stockholders are encouraged to submit their proxy by visiting http://www.viewproxy.com/ocuphire/2024 and entering their 11-digit control number. The agenda includes the election of seven director nominees. The appointment of Ernst & Young, LLP as the independent public accounting firm for the fiscal year ending December 31, 2024, will be ratified.
Why It Matters
For investors and stakeholders tracking Ocuphire Pharma, Inc., this filing contains several important signals. The virtual format allows for broader participation from stockholders regardless of location. The proxy statement outlines key corporate governance matters, including director elections and auditor ratification, which are crucial for shareholder oversight.
Risk Assessment
Risk Level: low — Ocuphire Pharma, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational news.
Analyst Insight
Review the director nominees and auditor ratification proposals to make an informed voting decision before the June 11th meeting.
Key Numbers
- 7 — Director Nominees (Number of director nominees to be elected at the Annual Meeting.)
- 2024-06-11 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders.)
- 4:00 p.m. ET — Annual Meeting Time (Time of the 2024 Annual Meeting of Stockholders.)
Key Players & Entities
- Ocuphire Pharma, Inc. (company) — Registrant and filer of the proxy statement.
- June 11, 2024 (date) — Date of the Annual Meeting of Stockholders.
- Ernst & Young, LLP (company) — Proposed independent public accounting firm.
- December 31, 2024 (date) — Fiscal year end for which Ernst & Young, LLP is proposed as auditor.
- 248-681-9815 (phone_number) — Business phone number for Ocuphire Pharma, Inc.
FAQ
When did Ocuphire Pharma, Inc. file this DEF 14A?
Ocuphire Pharma, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 29, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Ocuphire Pharma, Inc. (IRD).
Where can I read the original DEF 14A filing from Ocuphire Pharma, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Ocuphire Pharma, Inc..
What are the key takeaways from Ocuphire Pharma, Inc.'s DEF 14A?
Ocuphire Pharma, Inc. filed this DEF 14A on April 29, 2024. Key takeaways: Ocuphire Pharma, Inc. will hold its 2024 Annual Meeting of Stockholders on June 11, 2024, at 4:00 p.m. ET.. The meeting will be conducted virtually via live webcast, accessible at https://viewproxy.com/ocuphire/2024/htype.asp.. Stockholders are encouraged to submit their proxy by visiting http://www.viewproxy.com/ocuphire/2024 and entering their 11-digit control number..
Is Ocuphire Pharma, Inc. a risky investment based on this filing?
Based on this DEF 14A, Ocuphire Pharma, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational news.
What should investors do after reading Ocuphire Pharma, Inc.'s DEF 14A?
Review the director nominees and auditor ratification proposals to make an informed voting decision before the June 11th meeting. The overall sentiment from this filing is neutral.
How does Ocuphire Pharma, Inc. compare to its industry peers?
Ocuphire Pharma operates in the pharmaceutical preparations industry, focusing on developing therapies for ophthalmic conditions.
Are there regulatory concerns for Ocuphire Pharma, Inc.?
The filing is made under Schedule 14A of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.
Risk Factors
- Proxy Statement Filing Requirements [low — regulatory]: The company must comply with SEC regulations for filing proxy statements, including providing detailed information on director nominees and auditor appointments.
Industry Context
Ocuphire Pharma operates in the pharmaceutical preparations industry, focusing on developing therapies for ophthalmic conditions.
Regulatory Implications
The filing is made under Schedule 14A of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.
What Investors Should Do
- Review the list of director nominees and their qualifications.
- Evaluate the proposal to ratify the appointment of Ernst & Young, LLP as the independent auditor.
- Submit proxy vote by the deadline to ensure representation at the virtual annual meeting.
Key Dates
- 2024-06-11: Annual Meeting of Stockholders — Key date for voting on director nominees and auditor ratification.
Glossary
- Proxy Statement
- A document filed by a company with the SEC that contains information that management must provide to shareholders before their annual meeting, or before a special meeting at which they will vote on a corporate matter. (Provides essential information for shareholders to make informed voting decisions on company matters.)
- Definitive Proxy Statement
- A proxy statement that has been filed with the SEC and is available to the public, typically after any preliminary review. (Represents the final version of the proxy materials shareholders will receive for voting.)
Year-Over-Year Comparison
This is a DEF 14A filing, indicating it's the definitive proxy statement for the annual meeting, following any preliminary filings.
Filing Stats: 4,511 words · 18 min read · ~15 pages · Grade level 11.6 · Accepted 2024-04-29 16:28:49
Key Financial Figures
- $0.0001 — any’s common stock, par value of $0.0001 per share (the “Common Stock
Filing Documents
- ny20024296x2_def14a.htm (DEF 14A) — 993KB
- logo_ocuphire.jpg (GRAPHIC) — 33KB
- ny20024296x2_cgallagher.jpg (GRAPHIC) — 35KB
- ny20024296x2_five.jpg (GRAPHIC) — 7KB
- ny20024296x2_four.jpg (GRAPHIC) — 7KB
- ny20024296x2_gmagrath.jpg (GRAPHIC) — 36KB
- ny20024296x2_jpepose.jpg (GRAPHIC) — 35KB
- ny20024296x2_jsmanuso.jpg (GRAPHIC) — 34KB
- ny20024296x2_one.jpg (GRAPHIC) — 7KB
- ny20024296x2_pc02.jpg (GRAPHIC) — 757KB
- ny20024296x2_pvp01.jpg (GRAPHIC) — 153KB
- ny20024296x2_pvp02.jpg (GRAPHIC) — 161KB
- ny20024296x2_rrodgers.jpg (GRAPHIC) — 35KB
- ny20024296x2_sainsworth.jpg (GRAPHIC) — 34KB
- ny20024296x2_six.jpg (GRAPHIC) — 7KB
- ny20024296x2_skbenton.jpg (GRAPHIC) — 35KB
- ny20024296x2_three.jpg (GRAPHIC) — 7KB
- ny20024296x2_two.jpg (GRAPHIC) — 7KB
- ny20024296x2_pc01x1.jpg (GRAPHIC) — 632KB
- sig_georgemagrath.jpg (GRAPHIC) — 13KB
- sig_georgemagrathx1.jpg (GRAPHIC) — 9KB
- 0001140361-24-023004.txt ( ) — 3803KB
Executive Compensation
Executive Compensation ​ ​ 30 Proposal No. 3 Advisory Vote to Approve the Compensation of Our Named Executive Officers ​ ​ 43 Proposal No. 4 Approval, Pursuant to The Nasdaq Listing Rules, The Potential Issuance of Share of Common Stock to Lincoln Park Capital Fund, LLC In Excess of 19.99% of our Outstanding Common Stock ​ ​ 45 Proposal No. 5 Approval of an Amendment to The Certificate of Incorporation for the Exculpation of Officers ​ ​ 49 Proposal No. 6 Approval of an Amendment to The Certificate of Incorporation to Increase the Number of Authorized Shares of Our Common Stock from 75 Million Shares to 125 Million Shares. ​ ​ 51
Security Ownership of Certain Beneficial Owners and Management
Security Ownership of Certain Beneficial Owners and Management ​ ​ 53 Additional Information ​ ​ 56 Other Matters ​ ​ 58 TABLE OF CONTENTS General Information About the Meeting The Board of Directors (the “Board”) of Ocuphire Pharma, Inc. (the “Company”, “we”, “our” or “us”) solicits your proxy on our behalf for the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) and at any postponement or adjournment of the Annual Meeting for the purposes set forth in this Proxy Statement and the accompanying Notice of 2024 Annual Meeting of Stockholders (the “Notice”). The Annual Meeting will be held virtually via live audio webcast. You may attend the Annual Meeting via the internet, vote your shares and submit a question by first registering at https://viewproxy.com/ocuphire/2024/htype.asp using your Virtual Control Number that is on your proxy card. Your registration must be received by 11:59 p.m. Eastern Time on June 9, 2024. This Proxy Statement is first being sent to stockholders on or about April 29, 2024. The Annual Meeting will be completely virtual and conducted via live audio webcast. You will be able to attend the Annual Meeting by first registering at https://viewproxy.com/ocuphire/2024/htype.asp. You will receive a meeting invitation by e-mail with your unique join link along with a password prior to the meeting date. Stockholders will be able to listen, vote and submit questions during the virtual meeting. We have created and implemented the virtual format in order to facilitate stockholder attendance and participation by enabling stockholders to participate fully, and equally, from any location around the world, at no cost (with the exception of any costs associated with your Internet access, such as usage charges from Internet access providers and telephone companies). A virtual Annual Meeting mak